Search Results

Genetown

Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates

Nona Biosciences announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-generation bioconjugates.

November 13, 2023

·

3 min read

Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development

Thousand Oaks Biologics Inc. and GeneQuantum Healthcare Co., Ltd. are pleased to announce that they have formed a strategic partnership focusing on the CMC development of ADC products with a core conjugation technology for more stable drug candidates.

May 22, 2023

·

3 min read

Business

GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development

GeneQuantum and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, signed a collaboration agreement.

July 17, 2023

·

5 min read

Policy

GeneQuantum Healthcare’s Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare Co., Ltd. announced that two of the company’s bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum’s pipelines in the clinical stage.

May 15, 2022

·

2 min read

Business

GeneQuantum announces a key leadership appointment

GeneQuantum Healthcare announced a key appointment to further strengthen GeneQuantum management team.

August 15, 2021

·

2 min read

Business

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

GeneQuantum Healthcare Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic antibody drug conjugate.

April 18, 2022

·

3 min read

Business

GeneQuantum announces two key leadership appointments

GeneQuantum Healthcare announced the appointment of Dr. Li Wan as the Senior Vice President and Head of Global Regulatory Affairs, Dr. Weimeng Zhao as Vice President of Quality Research and Quality, to further strengthen the GeneQuantum management team.

September 15, 2021

·

3 min read

Business

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

GeneQuantum Healthcare Co.,Ltd. and BrighGene Biomedical Co.,Ltd. signed a co-development agreement for antibody immune agonist conjugate, GQ1007.

September 5, 2021

·

4 min read

Business

Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development

Samsung Biologics has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate for the treatment of non-small-cell lung carcinoma, triple-negative breast cancer, and other solid tumors.

November 1, 2020

·

3 min read

Drug Development

Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times

Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.

February 17, 2025

·

1 min read

·

Lori Ellis